Zenas BioPharma, Inc. (ZBIO)
ZBIONASDAQ-GSBiotechnology: Pharmaceutical Preparations
$28.01
+0.3700 (+1.34%) today
Closed, Nov 13, 4:00 PM ET
- Market cap
- $1.90bn
- P/E
- –
- EPS, last 4 quarters
- $-9.42
- Dividend yield
- –
- Day range
- –
- 52-week range
- $13.50 to $44.60
- Average volume
- –
- Previous close
- $27.64
Analysts
4 coveringBuy4 buy, 0 hold, 0 sell
Targets a year out average $44.80, +59.9% from here
Earnings
next estimate $-1.36Next report
Dec 2025
-272.1%
Mar 2026
-6.6%
Jun 2026
-98.9%
Sep 2026
-37.5%
estimate reported, and the surprise
Financials
| Quarter | Dec 2025 | Mar 2026 | Jun 2026 | Sep 2026 |
|---|---|---|---|---|
| Revenue | – | – | $1.00m | $10.00m |
| Gross profit | – | – | $1.00m | $10.00m |
| Operating income | -$237.98m | -$77.35m | -$107.66m | -$103.41m |
| Net income | -$240.44m | -$80.99m | -$111.46m | -$108.92m |
News
4 latest- Zenas BioPharma Reports Progress in Clinical Trials and Strengthens Leadership Team with New AppointmentsQuiver Quantitative · May 15, 2025
- Zenas BioPharma Appoints Dr. Lisa von Moltke as Head of Research and Development and Chief Medical OfficerQuiver Quantitative · Mar 17, 2025
- Insider Purchase: Director at $ZBIO Buys 10,000 SharesQuiver Quantitative · Feb 11, 2025
- Zenas BioPharma Advances Obexelimab Trials and Out-licenses Thyroid Eye Disease Programs in 2024 UpdateQuiver Quantitative · Feb 5, 2025
The company
Zenas is a clinical-stage global biopharmaceutical company committed to becoming a leader in the development and commercialization of transformative therapies for patients living with autoimmune diseases. Our core business strategy combines our experienced leadership team with a disciplined product candidate acquisition approach to identify, acquire and develop product candidates globally that we believe can provide superior clinical benefits to patients living with autoimmune diseases. Zenas is advancing two late-stage, potential franchise molecules, obexelimab and orelabrutinib. Obexelimab, Zenas' lead product candidate, is a bifunctional monoclonal antibody designed to bind both CD19 and FcRIIb, which are broadly present across B cell lineage, to inhibit the activity of cells that are implicated in many autoimmune diseases without depleting them.
- Sector
- Health Care
- Industry
- Biotechnology: Pharmaceutical Preparations
- Exchange
- NASDAQ-GS
- Region
- North America
- Website
- zenasbio.com
Often looked at with it
Figures from Yahoo, Nasdaq (Zacks consensus) and Lighter. Stocks can be minutes behind. Nothing here is advice.